抗菌素抗药性市场分析及预测（至2035年）：类型、产品类型、服务、技术、应用、最终用户、流程、部署类型、解决方案

预计抗菌素抗药性市场将从2024年的63亿美元成长到2034年的128亿美元，复合年增长率约为8.6%。抗菌素抗药性市场涵盖了应对病原体对标准疗法产生抗药性这一日益严峻挑战的解决方案，包括新型抗生素、诊断技术以及噬菌体疗法和益生菌等替代疗法。随着抗药性问题日益严重，公众意识的提高和监管支持的加强，使得人们迫切需要创新药物和技术来对抗感染疾病。该市场呈现出成长势头，凸显了研发、战略合作以及政府主导的各项倡议对于减轻抗药性在全球范围内的影响的重要性。

由于迫切需要新的治疗方法来对抗抗药性病原体，抗菌药物抗药性市场正经历显着增长。在治疗方法领域，抗生素细分市场成长最快，这主要得益于针对多重抗药性细菌的先进製剂的研发。抗病毒药物细分市场成长速度位居第二，这主要得益于为应对病毒抗药性挑战而开发的新型药物类别。在诊断领域，能够快速且准确地识别抗药性感染疾病的快速诊断测试占据主导。紧随其后的是分子诊断，它在检测抗药性基因方面具有更高的灵敏度和特异性。对抗菌药物管理计划日益增长的需求也进一步推动了市场成长，凸显了优化抗生素使用的重要性。疫苗作为一种预防措施正受到越来越多的关注，其中细菌疫苗已成为一个重要的细分市场。开发针对抗药性菌株的创新疫苗对于市场的长期永续性至关重要。製药公司与研究机构之间的合作对于促进创新和拓展治疗选择至关重要。

抗菌药物抗药性市场正经历市场份额、定价和产品发布方面的动态变化。随着对创新解决方案的日益关注，新参与企业正在挑战现有领导企业。定价策略竞争日益激烈，各公司都在努力平衡价格可负担性和最尖端科技进步。新产品的推出旨在满足未被满足的需求、提高疗效并最大限度地减少抗药性。市场产品种类繁多，各公司透过策略行销和分销管道争夺市场主导地位。竞争基准分析表明，主要参与者不断创新以保持其竞争优势。监管影响至关重要，严格的指导方针影响产品开发和市场准入。各公司透过投资合规和遵守国际标准来应对这些法规。在技​​术进步和人们对抗菌药物抗药性日益增长的认识的推动下，市场蓄势待发，即将迎来成长。随着各公司寻求扩展产品系列和巩固市场地位，策略联盟和併购活动日益频繁。

主要趋势和驱动因素：

抗菌素抗药性（AMR）市场正经历显着成长，这主要得益于人们对抗生素滥用和过度使用的认识不断提高。各国政府和卫生组织已将AMR列为重要的公共卫生议题，并加强了研发投入。这一趋势推动了诊断技术和新型抗菌药物的研发。抗药性感染疾病的日益普遍也促使人们开发新的治疗策略，这也是市场成长的关键驱动因素。製药业正在探索对抗抗药性的替代方法，例如噬菌体疗法和抗菌肽。此外，人工智慧和机器学习等先进技术在药物发现过程中的应用，使得高效识别有前景的候选药物成为可能。同时，法规结构的发展旨在简化新抗菌药物的核准流程，鼓励企业投资这个充满挑战却又前景看好的市场。公私合营也伙伴关係出现，凸显了全球携手对抗AMR的努力。对于能够适应不断变化的抗菌素抗药性情况并进行创新的企业而言，机会比比皆是。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

• 宏观经济分析
• 市场趋势
• 市场驱动因素
• 市场机会
• 市场限制
• 复合年均成长率：成长分析
• 影响分析
• 新兴市场
• 技术蓝图
• 战略框架

第四章 细分市场分析

• 市场规模及预测：依类型
  • 抗生素
  • 抗病毒药物
  • 抗真菌剂
  • 抗寄生虫药物
  • 消毒剂
• 市场规模及预测：依产品划分
  • 製药
  • 疫苗
  • 诊断试剂盒
  • 感染预防产品
• 市场规模及预测：依服务划分
  • 咨询
  • 检查室检测
  • 监控服务
  • 教育和培训
• 市场规模及预测：依技术划分
  • 基因组学
  • 蛋白质体学
  • 奈米科技
  • 生物资讯学
• 市场规模及预测：依应用领域划分
  • 院内感染
  • 社区型感染
• 市场规模及预测：依最终用户划分
  • 医院和诊所
  • 製药公司
  • 研究所
  • 政府和监管机构
• 市场规模及预测：依製程划分
  • 药物发现
  • 药物研发
  • 临床试验
  • 监管部门核准
• 市场规模及预测：依发展状况
  • 本地部署
  • 基于云端的
• 市场规模及预测：按解决方案划分
  • 抗菌药物管理计划
  • 感染控制解决方案

第五章 区域分析

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地区
• 亚太地区
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲
  • 台湾
  • 亚太其他地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利
  • 其他欧洲地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非
  • 撒哈拉以南非洲
  • 其他中东和非洲地区

第六章 市场策略

• 需求与供给差距分析
• 贸易和物流限制
• 价格、成本和利润率趋势
• 市场渗透率
• 消费者分析
• 法规概述

第七章 竞争讯息

• 市场定位
• 市场占有率
• 竞争基准
• 主要企业的策略

第八章 公司简介

• Melinta Therapeutics
• Nabriva Therapeutics
• Paratek Pharmaceuticals
• Achaogen
• Iterum Therapeutics
• Venatorx Pharmaceuticals
• Aridis Pharmaceuticals
• Motif Bio
• Spero Therapeutics
• Scynexis
• Cidara Therapeutics
• Summit Therapeutics
• Entasis Therapeutics
• Forge Therapeutics
• Debiopharm Group
• Macrolide Pharmaceuticals
• Qpex Biopharma
• Bugworks Research
• Antabio
• Nosopharm

第九章：关于我们

Antimicrobial Resistance Market is anticipated to expand from $6.3 billion in 2024 to $12.8 billion by 2034, growing at a CAGR of approximately 8.6%. The Antimicrobial Resistance Market encompasses solutions addressing the growing challenge of pathogens resistant to standard treatments. This includes novel antibiotics, diagnostics, and alternative therapies such as phage therapy and probiotics. As resistance escalates, there is an urgent demand for innovative drugs and technologies to combat infections, driven by increased awareness and regulatory support. The market is poised for growth, emphasizing research and development, strategic collaborations, and government initiatives to mitigate resistance impact globally.

The Antimicrobial Resistance Market is experiencing notable growth, driven by the urgent need for novel therapeutics to combat resistant pathogens. Within the therapeutic segment, the antibiotics sub-segment is the top performer, fueled by the development of advanced formulations targeting multi-drug resistant strains. The second highest performing sub-segment is the antivirals, as new drug classes are designed to address viral resistance challenges. In the diagnostics segment, rapid diagnostic tests lead the way, providing timely and precise identification of resistant infections. Molecular diagnostics follow closely, offering enhanced sensitivity and specificity in detecting resistance genes. The rising demand for antimicrobial stewardship programs further propels market growth, emphasizing the importance of optimizing antibiotic use. Preventative measures, such as vaccines, are gaining momentum, with bacterial vaccines being the leading sub-segment. The development of innovative vaccines targeting resistant strains is crucial for long-term market sustainability. Collaborative efforts between pharmaceutical companies and research institutions are pivotal, fostering innovation and expanding treatment options.

The antimicrobial resistance market is experiencing dynamic shifts in market share, pricing, and product launches. A growing emphasis on innovative solutions is prompting new entrants to challenge established leaders. Pricing strategies are increasingly competitive, with companies seeking to balance affordability with cutting-edge advancements. New product launches are focusing on addressing unmet needs, enhancing efficacy, and minimizing resistance. The market is characterized by a diverse range of products, each vying for prominence through strategic marketing and distribution channels. Competition benchmarking reveals a landscape where key players are continuously innovating to maintain their competitive edge. Regulatory influences play a crucial role, with stringent guidelines shaping product development and market entry. Companies are navigating these regulations by investing in compliance and aligning with global standards. The market is poised for growth, driven by technological advancements and heightened awareness of antimicrobial resistance. Strategic partnerships and mergers are becoming prevalent, as firms seek to expand their portfolios and enhance their market position.

Geographical Overview:

The antimicrobial resistance market is witnessing varied growth across different regions, with unique opportunities emerging. North America leads the market, propelled by substantial investments in research and development and a robust healthcare infrastructure. The region's focus on innovative solutions to combat resistance has spurred significant advancements. Europe follows closely, driven by stringent regulations and a strong emphasis on public health initiatives. The region's collaborative efforts in research and policy-making are fostering a conducive environment for market expansion. Asia Pacific is rapidly becoming a key growth pocket, with increasing awareness and governmental support driving the market. Emerging economies like India and China are at the forefront, investing heavily in healthcare infrastructure and novel antimicrobial solutions. Latin America and the Middle East & Africa are also showing promising potential. These regions are increasingly recognizing the importance of addressing antimicrobial resistance, with growing investments in healthcare systems and international collaborations.

The global antimicrobial resistance (AMR) market is intricately influenced by tariffs, geopolitical risks, and evolving supply chain paradigms. In Japan and South Korea, strategic investments in biotechnology and pharmaceutical innovation are mitigating tariff impacts, while China accelerates its focus on localizing drug production to counteract export restrictions. Taiwan, with its robust pharmaceutical manufacturing base, remains a pivotal player but is vulnerable to regional tensions. The global AMR market is witnessing robust growth due to heightened awareness and regulatory support, yet faces supply chain vulnerabilities. By 2035, the market is poised for significant expansion, driven by technological advancements and international collaborations. Middle East conflicts continue to exert pressure on global energy prices, indirectly affecting manufacturing and logistics costs within the AMR supply chain.

Key Trends and Drivers:

The Antimicrobial Resistance (AMR) market is experiencing substantial growth driven by increasing awareness of antibiotic misuse and overuse. Governments and health organizations are prioritizing AMR as a critical public health issue, leading to heightened investments in research and development. This trend is fostering innovations in diagnostics and novel antimicrobial agents. A significant driver is the rising prevalence of drug-resistant infections, which necessitates the development of new treatment strategies. The pharmaceutical industry is exploring alternative approaches, such as bacteriophage therapy and antimicrobial peptides, to combat resistant strains. Another trend is the integration of advanced technologies like AI and machine learning in drug discovery, enhancing the efficiency of identifying potential candidates. Additionally, regulatory frameworks are evolving to streamline the approval process for new antimicrobials, encouraging companies to invest in this challenging yet promising market. Partnerships between public and private sectors are also emerging, focusing on collaborative efforts to address AMR globally. Opportunities abound for companies that can innovate and adapt to the dynamic landscape of antimicrobial resistance.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Deployment
• 2.9 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Antibiotics
  • 4.1.2 Antivirals
  • 4.1.3 Antifungals
  • 4.1.4 Antiparasitics
  • 4.1.5 Disinfectants
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Drugs
  • 4.2.2 Vaccines
  • 4.2.3 Diagnostic Kits
  • 4.2.4 Infection Prevention Products
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consulting
  • 4.3.2 Laboratory Testing
  • 4.3.3 Surveillance Services
  • 4.3.4 Education and Training
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Genomics
  • 4.4.2 Proteomics
  • 4.4.3 Nanotechnology
  • 4.4.4 Bioinformatics
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Hospital-acquired Infections
  • 4.5.2 Community-acquired Infections
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals and Clinics
  • 4.6.2 Pharmaceutical Companies
  • 4.6.3 Research Laboratories
  • 4.6.4 Government and Regulatory Bodies
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Drug Discovery
  • 4.7.2 Drug Development
  • 4.7.3 Clinical Trials
  • 4.7.4 Regulatory Approval
• 4.8 Market Size & Forecast by Deployment (2020-2035)
  • 4.8.1 On-premise
  • 4.8.2 Cloud-based
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Antimicrobial Stewardship Programs
  • 4.9.2 Infection Control Solutions

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Process
    • 5.2.1.8 Deployment
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Process
    • 5.2.2.8 Deployment
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Process
    • 5.2.3.8 Deployment
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Process
    • 5.3.1.8 Deployment
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Process
    • 5.3.2.8 Deployment
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Process
    • 5.3.3.8 Deployment
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Process
    • 5.4.1.8 Deployment
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Process
    • 5.4.2.8 Deployment
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Process
    • 5.4.3.8 Deployment
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Process
    • 5.4.4.8 Deployment
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Process
    • 5.4.5.8 Deployment
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Process
    • 5.4.6.8 Deployment
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Process
    • 5.4.7.8 Deployment
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Process
    • 5.5.1.8 Deployment
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Process
    • 5.5.2.8 Deployment
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Process
    • 5.5.3.8 Deployment
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Process
    • 5.5.4.8 Deployment
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Process
    • 5.5.5.8 Deployment
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Process
    • 5.5.6.8 Deployment
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Process
    • 5.6.1.8 Deployment
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Process
    • 5.6.2.8 Deployment
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Process
    • 5.6.3.8 Deployment
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Process
    • 5.6.4.8 Deployment
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Process
    • 5.6.5.8 Deployment
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Melinta Therapeutics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Nabriva Therapeutics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Paratek Pharmaceuticals
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Achaogen
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Iterum Therapeutics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Venatorx Pharmaceuticals
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Aridis Pharmaceuticals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Motif Bio
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Spero Therapeutics
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Scynexis
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Cidara Therapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Summit Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Entasis Therapeutics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Forge Therapeutics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Debiopharm Group
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Macrolide Pharmaceuticals
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Qpex Biopharma
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Bugworks Research
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Antabio
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Nosopharm
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us